

Initial Therapy of Chronic Lymphocytic Leukemia

B. Eichhorst, P. Cramer, M. Hallek



PII: S0093-7754(16)00011-7
DOI: <http://dx.doi.org/10.1053/j.seminoncol.2016.02.005>
Reference: YSONC51909

To appear in: *Semin Oncol*

Cite this article as: B. Eichhorst, P. Cramer, M. Hallek, Initial Therapy of Chronic Lymphocytic Leukemia, *Semin Oncol*, <http://dx.doi.org/10.1053/j.seminoncol.2016.02.005>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Initial therapy of chronic lymphocytic leukemia

B Eichhorst¹, P Cramer¹, M Hallek^{1,2}

¹ Department I for Internal Medicine and Center of Integrated Oncology, University of Cologne, Cologne, Germany

² CECAD - Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Diseases

Corresponding author:

Barbara Eichhorst, MD, Department I of Internal Medicine and Center of Integrated Oncology Köln Bonn, University of Cologne, Köln, Germany. Email: barbara.eichhorst@uk-koeln.de.

Phone: 0049-221/478-85255

Disclosures

The authors received research funding and honoraria for scientific talks and advisory boards from the following pharmaceutical companies: Celgene, Gilead, GSK, Hoffmann LaRoche, Janssen and Mundipharma. MH was supported by the Deutsche Forschungsgemeinschaft, clinical research unit 286 (KFO 286)

Abstract

Only CLL patients with active or symptomatic disease or with advanced Binet or Rai stages require therapy. Prognostic risk factor profile and comorbidity burden are most relevant for the choice of treatment. For physically fit patients, chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab remains the current standard therapy. For unfit patients, treatment with an anti-CD20 antibody (obinutuzumab or rituximab or ofatumumab) plus milder chemotherapy (chlorambucil)

Download English Version:

<https://daneshyari.com/en/article/2161748>

Download Persian Version:

<https://daneshyari.com/article/2161748>

[Daneshyari.com](https://daneshyari.com)